Osaka, Japan – August 28, 2026
Shionogi & Co., Ltd. announced that the Biomedical Advanced Research and Development Authority (BARDA) has exercised a $36.9 million procurement option under its Project BioShield contract to procure Fetroja® (cefiderocol) as a critical countermeasure against difficult-to-treat Gram-negative bacterial infections and pathogens considered high-priority biothreats. The procurement represents the first exercised option under Shionogi’s April 2026 U.S. government contract, which initially included $119 million in funding and provides multiyear procurement and related options potentially totaling up to $482 million. The development strengthens the role of Fetroja within U.S. national preparedness efforts against drug-resistant bacterial threats, while expanding Shionogi’s collaboration with BARDA around antimicrobial preparedness and pharmaceutical manufacturing capabilities.
Shionogi Expands Fetroja Role in National Preparedness
The $36.9 million BARDA procurement is focused on supporting U.S. preparedness against difficult-to-treat bacterial infections and pathogens that could pose significant risks to national health security. The order forms part of a broader government-backed program designed to strengthen access to medical countermeasures for high-priority biological threats. Under the overall agreement, additional options include activities related to establishing a U.S. drug product manufacturing site for Fetroja, advancing the antibiotic for infections caused by high-priority biothreat pathogens and expanding its potential use in pediatric patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) through an FDA Supplemental New Drug Application. For Shionogi, the procurement provides a concrete step in translating the broader Project BioShield agreement into government-supported supply and preparedness activity, while reinforcing the company’s long-standing focus on infectious disease and antimicrobial resistance.
Fetroja Supports Response to Drug-Resistant Gram-Negative Infections
Fetroja (cefiderocol) is an antibiotic designed to address serious infections caused by susceptible Gram-negative bacteria, an important area of concern as antimicrobial resistance continues to limit treatment options. In the United States, Fetroja is approved for the treatment of adult patients with complicated urinary tract infections, including pyelonephritis, and HABP/VABP caused by certain susceptible Gram-negative bacteria. The BARDA program adds a national preparedness dimension to the product by focusing on its potential role against pathogens associated with high-priority biothreat scenarios. Shionogi has more than 60 years of experience in anti-infective research and commercialization, and the company continues to develop programs addressing antimicrobial resistance and other infectious disease challenges. The government procurement therefore represents not simply a commercial supply agreement but an expansion of Fetroja’s strategic importance within U.S. antimicrobial and biodefense preparedness.
Advertisement
Shionogi Advances $482M Project BioShield Collaboration
The exercised option is the first of several procurement and development opportunities included in Shionogi’s Project BioShield contract, which could reach approximately $482 million across its multiyear options. The agreement also supports efforts to establish domestic manufacturing capacity for Fetroja and investigate additional applications that could increase the product’s utility against high-priority pathogens. The latest procurement provides near-term validation of the collaboration, while the remaining options could create additional milestones for Shionogi as the company works with U.S. government agencies on drug-resistant bacterial threat preparedness. The company also continues initiatives intended to improve responsible access to antibiotics internationally through partnerships addressing antimicrobial resistance. For cGxP.wire, the key development is the $36.9 million BARDA procurement and its connection to the larger potential $482 million Project BioShield program, positioning Fetroja as an important component of U.S. preparedness against difficult-to-treat bacterial threats.
Source: Shionogi, press relese
